Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study

Basit Öğe Kaydı
dc.authoridSaygili, Seha Kamil/0000-0002-2424-6959
dc.authoridOzcelik, Gul/0000-0001-9394-2977
dc.authoridCanpolat, Nur/0000-0002-3420-9756
dc.authoridTaşdemir, Mehmet/0000-0002-5579-6339
dc.authoridÇELAKIL, MEHTAP/0000-0002-5354-1455
dc.authoridTurkkan, Ozde Nisa/0000-0003-2928-9031
dc.authoridBalat, Ayse/0000-0002-8904-1348
dc.authorwosidSaygili, Seha Kamil/GLU-6742-2022
dc.authorwosidCandan, Cengiz/ABC-6193-2021
dc.authorwosidOzcelik, Gul/GQQ-3364-2022
dc.authorwosidCanpolat, Nur/AHE-2082-2022
dc.authorwosidTülpar, Sebahat/GQP-4951-2022
dc.authorwosidTaşdemir, Mehmet/V-7413-2017
dc.authorwosidÇELAKIL, MEHTAP/JCE-7313-2023
dc.contributor.authorTasdemIr, Mehmet
dc.contributor.authorCanpolat, Nur
dc.contributor.authorYildiz, Nurdan
dc.contributor.authorOzcelIk, Gul
dc.contributor.authorBenzer, Meryem
dc.contributor.authorSaygili, Seha Kamil
dc.contributor.authorOzkayin, Emine Nese
dc.date.accessioned2024-06-12T11:02:17Z
dc.date.available2024-06-12T11:02:17Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to-treat nephrotic syndrome, considering the type of disease (steroid-sensitive or -resistant) and the dosing regimen. Materials and methods: This multicenter retrospective study enrolled children with difficult-to-treat nephrotic syndrome on rituximab treatment from 13 centers. The patients were classified based on low (single dose of 375 mg/m(2)) or high (2-4 doses of 375 mg/m(2)) initial dose of rituximab and the steroid response. Clinical outcomes were compared. Results: Data from 42 children [20 steroid-sensitive (frequent relapsing / steroid-dependent) and 22 steroid-resistant nephrotic syndrome, aged 1.9-17.3 years] were analyzed. Eleven patients with steroid-sensitive nephrotic syndrome (55%) had a relapse following initial rituximab therapy, with the mean time to first relapse of 8.4 +/- 5.2 months. Complete remission was achieved in 41% and 36% of steroid-resistant patients, with the median remission time of 3.65 months. At Year 2, eight patients in steroid-sensitive group (40%) and four in steroid-resistant group (18%) were drug-free. Total cumulative doses of rituximab were higher in steroid-resistant group (p = 001). Relapse rates and time to first relapse in steroid-sensitive group or remission rates in steroid-resistant group did not differ between the low and high initial dose groups. Conclusion: The current study reveals that rituximab therapy may provide a lower relapse rate and prolonged relapse-free survival in the steroid-sensitive group, increased remission rates in the steroid-resistant group, and a significant number of drug-free patients in both groups. The optimal regimen for initial treatment and maintenance needs to be determined.en_US
dc.identifier.doi10.3906/sag-2012-297
dc.identifier.endpage1790en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue4en_US
dc.identifier.pmid33581711en_US
dc.identifier.scopus2-s2.0-85114376044en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1781en_US
dc.identifier.trdizinid480445en_US
dc.identifier.urihttps://doi.org/10.3906/sag-2012-297
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/480445
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21208
dc.identifier.volume51en_US
dc.identifier.wosWOS:000691544700025en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technological Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal Of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectFrequently Relapsing Nephrotic Syndromeen_US
dc.subjectImmunosuppressive Agentsen_US
dc.subjectSteroid-Dependent Nephrotic Syndromeen_US
dc.subjectSteroid-Resistant Nephrotic Syndromeen_US
dc.subjectRemissionen_US
dc.subjectChildhood-Onseten_US
dc.subjectFollow-Upen_US
dc.subjectCyclosporineen_US
dc.titleRituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu